

Date: October 12, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub: Submission of Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2026

In compliance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find enclosed herewith Reconciliation of Share Capital Audit Report, dated October 10, 2026 duly signed and issued by Mr. Tapan Shah, Company Secretary in Practice, for the quarter ended on September 30, 2026.

Kindly take the same on your records.

Thanking you.

For Senores Pharmaceuticals Limited

SHILPA SHARMA
Digitally signed by SHILPA SHARMA
DN: cn=SHILPA SHARMA, c=IN,
o=Personal,
email=csshilpa.agarwal@gmail.com
Date: 2026.10.12 16:54:45 +05'30'

Shilpa Sharma
Company Secretary and Compliance Officer
ICSI Membership No.: A34516

Encl.: As mentioned above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

To,
 The Board of Directors,
SENORES PHARMACEUTICALS LIMITED,
 1101 to 1103, 11th floor, South Tower, ONE 42,
 Opp. Jayantilal Park, Ambali Bopal Road,
 Ahmedabad, Gujarat, India, 380054

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

CIN : L24290GJ2017PLC100263
 Authorised Capital : Rs. 59,00,00,000

I have examined the Register of Members, beneficiary details given by the Depositories and other records / documents maintained by **M/s. SENORES PHARMACEUTICALS LIMITED**, having its Registered Office at 1101 to 1103, 11th floor, South Tower, ONE 42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054 for issuing Certificate, in accordance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 read with Circular D&CC/FITTC/CIR-16/2002 dated December 31, 2002 issued by the Securities and Exchange Board of India (SEBI). To the best of my knowledge and according to the information and explanation given to me and as per the record received through mail and examined by me, I hereby certify that for the quarter ended 30th September, 2026, the details of position of Company's Capital Structure, its Equity shares position with NSDL, CDSL and in Physical form, the Demat activity carried out and any pending Demat status and other details are as under:

1	For Quarter Ended	30/09/2026
2	ISIN	INE0RB801010
3	Face Value	Rs. 10/- per Share
4	Name of the Company	SENORES PHARMACEUTICALS LIMITED
5	Registered Office Address	1101 to 1103, 11 th floor, South Tower, ONE 42 Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad, Ahmedabad, Gujarat, India, 380054.
6	Correspondence Address	-- Same as above --
7	Telephone & Fax Nos.	Tel. 079- 29999857
8	Email Address	cs@senorespharma.com
9	Name of the Stock Exchanges where the Company's Securities are listed with scrip code	1. National Stock Exchange of India Limited. (Symbol: SENORES) 2. BSE Limited (Scrip Code: 544319)



10	Issued Equity Share Capital			No. of Shares			
				4,60,53,588			
11	Listed Equity Capital (as per company records)			4,60,53,588			
				No. of shares	% of issued Capital		
12	Held in dematerialized form in NSDL			3,04,14,742	66.04		
13	Held in dematerialized form in CDSL			1,56,38,846	33.96		
14	Physical			0	0		
15	Total No. of Shares (12+13+14)			4,60,53,588	100.00		
16	Reason for difference, if any, between (10&11), (11 & 15)			N.A.			
17	Certifying details of changes in share capital during the quarter under consideration as per Table below :						
Particulars	No. of Shares	Applied/ not Applied for Listing	Listed Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimate d to NSDL	In-principle Approval Pending for SE (Specify Names)	
NA	NA	NA	NA	NA	NA	NA	
18	Register of Members is updated (YES/NO) if not, updated up to which date			Yes			
19	Reference of previous quarter with regards to excess dematerialized shares, if any			-- N.A. --			
20	Has the company resolved the matter mentioned in point no. 19 above in the current quarter? If not, reason why?			-- N.A. --			
21	Mentioned the total no. of requests, confirmed after 21 days and the total no. of requests pending beyond 21 days (in both cases, from the date of DRN & confirmed by the Registrar is taken), with the reasons for delay:						
Total No. of demat requests			No. of requests		No. of shares		Reasons for delay
			NSDL	CDSL	NSDL	CDSL	N.A.
Confirmed after 21 days			--	--	--	--	
Pending for more than 21 Days			--	--	--	--	

22	Name, Telephone & Fax No. of Compliance Officer of the Co. (w.e.f. 26/08/2026)	Mrs. Shilpa Sharma, Company Secretary and Compliance Officer. Tel.: +91-79-29999857 E-mail: cs@senorespharma.com
23	a) Name, Address, Tel. & Fax No. of the Company Secretary in whole-time(to the extent applicable to SME Listed Company) practice	Mr. Tapan Shah (CP No.2839) 816-818, Anand Mangal-3, Nr. Doctor House, Ellisbridge, Ahmedabad-6 Tel.: 40024320 E-Mail: info@tapanshah.in
24	Appointment of Common Agency for Share Registry Work (Name & Address)	MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited) C 101, Embassy 247, L.B, S. Marg, Vikhroli (West), Mumbai-400083, Maharastra, India. Tel:+91 8108114949 , Fax-022-49186060, E-mail: investor.helpdesk@in.mpms.mufg.com
25	Any other detail that the Co. Secretary may like to provide (e.g. BIFR Co., delisting from SE, Company changed its name etc.)	- Appointment and categorization of Ms. Anjali Shah, Assistant Vice President-Finance as Senior Management Personnel (“SMP”) of the Company with effect from July 27, 2026. - Mrs. Shilpa Sharma, an Associate Member of the Institute of Company Secretaries of India (Membership No.: A34516), has been appointed as the Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company w.e.f. August 26, 2026. - Mr. Viranchi Arvindbhai Shah (DIN: 01598001) has been appointed as a Non-Executive Independent Director of the Company for a period of five (5) consecutive years commencing from August 26, 2026 to August 25, 2031, as approved by members in their meeting held on 25th September, 2026.

	• The Company has introduced the Senores Pharmaceuticals Employee Stock Option Scheme 2026 (ESOS 2026) to grant up to 4,72,000 stock options to eligible employees of the Company and its subsidiary companies, subject to the Scheme's terms and conditions, as approved by members in their meeting held on 25th September, 2026. • The company entered into Material Related Party Transactions within its various subsidiaries/ Step down subsidiaries Companies, as approved by members through postal ballot as on 3 August 2026. • The Company has enhanced the existing limits under Sections 185 and 186 (to advance any loan/ give guarantee/ provide security) of the Companies Act, 2013, up to an aggregate amount not exceeding ₹750 crore under each section, as approved by members through postal ballot as on 3 August 2026. • The members approved variation in the objects / terms of utilisation of the initial public offering ("IPO") proceeds and extension of time limit for utilisation of the IPO proceeds, as approved by members through postal ballot as on 3 August 2026.
--	--

Place : Ahmedabad
Date : 10/10/2026

TAPAN
RAJNIKANT
Signature: SHAH
Name of Company Secretary: TAPAN SHAH
C. P. Number: 2839
UDIN: F004476H001801865

Digitally signed by
TAPAN RAJNIKANT
SHAH
Date: 2026.10.10
10:27:34 +05'30'

Note:

Above report was prepared based on the softcopy of the papers/ report/ documents provided by the Share Registry of the Company, i.e. MUFG Intime India Private Limited. (Formerly known as Link Intime India Private Limited)

